Source: Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Csanadi, M. E. Zeller, A. Miczak, T. Rose, T. Bizebard, V. R. Kaberdin (Vienna, Austria; Szeged, Hungary; Paris, France). Towards new antituberculotic targets: biochemical characterisation of mycobacterial RNase E/G. Eur Respir J 2007; 30: Suppl. 51, 404

Member's Comments

No comment yet.

Related content which might interest you: Towards new antituberculotic targets: biochemical characterisation of mycobacterial RNase E/G Source: Eur Respir Rev 2008; 17: 76-77 Year: 2008 Comparative mycobacterial genomics as a tool for drug target and antigen discovery Source: Eur Respir J 2002; 20: 78S-86S Year: 2002 Molecular epidemiology of tuberculosis Source: Eur Respir J 2002; 20: 54S-65S Year: 2002 Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Comparative analysis of detection of Mycobacterium tuberculosis and rifampin resistance determination through microbiological and molecular genetics methods for pulmonary tuberculosis patients with presence or absence of sputum Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012 Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods Source: Eur Respir J, 51 (5) 1702189; 10.1183/13993003.02189-2017 Year: 2018 Novel NTM treatments and approaches, repurposed to bacteriophages Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment Year: 2021 The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis with HPLC technique - comparison to the conventional methods Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005 Standardised PCR-based molecular epidemiology of tuberculosis Source: Eur Respir J 2008; 31: 1077-1084 Year: 2008 Molecular epidemiology, drug resistance, and treatment of tuberculosis in Germany: preliminary results Source: Eur Respir J 2003; 22: Suppl. 45, 485s Year: 2003 Efficiency of molecular methods for epidemiological investigation in tuberculosis (TB) Source: Annual Congress 2012 - Tuberculosis: epidemiological and public health features Year: 2012 Quantitative membrane proteomics reveals new functions ofCD13 in mycobacterium tuberculosis infection Source: International Congress 2015 – Biomarkers in TB: immunology and physiology Year: 2015 Improved tracking of nosocomial transmission of multidrug resistant M. tuberculosis with a novel T cell-based test Source: Eur Respir J 2003; 22: Suppl. 45, 167s Year: 2003 Traditional and molecular diagnosis of tuberculosis and atypical mycobacteria Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease Year: 2004 A fully molecular drug sensitivity pattern for M.tuberculosis complex: what is available today and what is in the pipeline Source: International Congress 2017 – How to manage difficult tuberculosis cases: diagnosis and treatment Year: 2017 First experience with novel molecular diagnostic method for detection of M. tuberculosis and rifampicin resistance Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011